Print Page    Close Window    

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We ar... more >

Stock Quotemore >
C
$2.14
0.00 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 01/16/18 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
01/03/18
Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that the first patient has been randomized into a Phase 2b study evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).  The first patient was treated at The Lung Research Center in Chesterfield, MO, by Neil A. Ettinger, M.D. The iNO-PF Phase 2b, randomized, double-blind, placebo-cont... 
11/30/17
Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors
WARREN, N.J., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the appointment of Ted Wang, Ph.D., Chief Investment Officer of Puissance Capital Management, to its Board of Directors.  Bellerophon’s Board now includes 10 members. Dr. Wang is the Chief Investment Officer of Puissance Capital Management, a global asset manager founded in 2015 with offices in the U.S. and China. Puissance was the lead inve... 
11/07/17
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
WARREN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2017. “We continue to achieve important progress in all three of our INOpulse® clinical development programs,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics.  “In our INOvation-1 Phase 3 trial for Pulmonary Arterial Hyperten... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

© Bellerophon Therapeutics. All rights reserved.